Merck closed the fourth quarter with earnings and revenue ahead of Wall Street estimates, supported by strong demand for its blockbuster cancer drug Keytruda and accelerating sales from newer medicines. The performance, however, was tempered by guidance for 2026 that landed below expectations, reflecting the growing impact of patent expirations and pricing pressures. As several
Zilliqa (ZIL) is one of the best performers among the top 200 cryptocurrencies by market cap after adding 71% to its value in the last 24 hours. The rally comes ahead of its upcoming Cancun upgrade this week, with investors optimistic about ZIL despite the broader weakness in the crypto market. The strong buying interest
US futures largely gained on Tuesday ahead of the market open as investors digested a strong start to the month for US equities and prepared for a heavy slate of corporate earnings. Market sentiment was shaped by upbeat results from select technology names, volatility in commodities and crypto, and renewed focus on returns from artificial
Palantir stock price rebounded by over 6% in the extended hours after the software company published strong results that beat analysts’ estimates. PLTR jumped to $158, up substantially from the year-to-date low of $146. So, will it continue rising as a major risky pattern forms? Palantir published strong financial results Palantir, the company that Alex
With Brent crude trading in the $65–$70 corridor and a 2.3 million barrels per day (bpd) global surplus pressuring prices, Igor Isaev, Doctor of Technical Sciences and Head of Analytics at Mind Money, sees no near-term catalysts for a breakout higher. In an exclusive interview with Invezz, Isaev discusses persistent oversupply, Venezuela’s infrastructure challenges, Iran’s
PayPal reported a weaker-than-expected fourth quarter and issued a subdued profit forecast for 2026, underscoring mounting pressure from slowing consumer spending and intensifying competition in digital payments. The company said it expects full-year adjusted profit to decline in the low-single digit percentage to increase slightly, far below Wall Street expectations of roughly 8% growth, according
Pfizer reported fourth-quarter results that beat expectations, offering a steadier earnings picture as the company moves further away from the Covid-driven revenue surge of recent years. While demand for its pandemic-era products continues to fade, the pharmaceutical group is refocusing its strategy around pipeline development, targeted acquisitions, and large-scale cost reductions. The latest earnings update
The US economy has recently taken hits that would have stalled most developed systems. Tariffs were announced and withdrawn, then reintroduced. Trade relationships were tested. Government spending surged while policy direction changed repeatedly. But despite all that, growth stayed firm and markets kept moving higher. The US President argues that’s a sign of hidden strength.
Nio stock price continued its recent downward trend even after the company announced a big increase in its January deliveries. It crashed to a low of $4.52, its lowest level since August last year and 43% below its highest point in September last year. This article explores whether it is safe to buy the dip.
Polygon’s POL is one of the best performers among the top 100 cryptocurrencies by market cap. The coin takes a breather above $0.11 after adding 11% to its value in the last 24 hours. The rally comes as Polygon recorded its largest monthly burn of more than 25 million POL tokens in January. This latest